Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

Share Price is delayed by 15 minutes
Get Live Data
77.70    -7.30 (-8.59%)
Bid:
76.50
Ask:
77.80
Spread: 1.30 (1.699%)
Market Cap: £127.38m
SYNT Live PriceLast checked at - London Stock Exchange

Intraday Synthomer Share Chart

Q3 Trading update

9 Nov 2016 07:00

RNS Number : 6789O
Synthomer PLC
09 November 2016
 

 

November 9th 2016

Synthomer plc

Q3 Trading update

Positive performance and Full Year 2016 guidance maintained

Synthomer plc ('Synthomer' or 'the Group') today issues a trading update for the third quarter ('Q3') ended September 30th, 2016.

Trading

Europe and North America

Europe and North America has continued to trade well, in line with our expectations and consistent with the positive trends experienced through H1 2016. Q3 reported volumes were in line with last year whilst reported unit margins for the quarter were ahead of Q3 2015 and Q2 2016. Accordingly, with the exception of Paper latex, gross margins across all businesses were stronger than last year. This performance reflects the improved trading environment as well as the Group's focus on efficiency, new product initiatives, strengthened procurement function and investment in business development activities.

Asia and Rest of World

Asia and Rest of World has continued to trade in line with our expectations, with the competitive dynamics in our Asian Nitrile business evolving broadly as expected following the introduction of additional industry capacity.

Reported Asian volumes were marginally lower than last year but sequentially higher than Q2 2016, largely driven by increased volumes in the Asian Nitrile business. As expected, the market environment has led to overall unit margins softening from the highs seen in H2 2015 and H1 2016. Whilst the competitive dynamics in our Asian Nitrile business are continuing to evolve, this downward price pressure has not been as marked as the Group experienced in previous years. We continue to expect full year volumes and margins for this business to be similar to FY 2015.

Hexion PAC

The integration of Hexion PAC is well underway and progressing to plan. The underlying annual EBITDA and expected synergies remain unchanged from the guidance given to the market in March 2016.

Foreign currency

The Group has continued to benefit from the translation effect of the ongoing weakness of sterling. Average YTD FX rates are €1.24 and $1.38 which, if unchanged for the remainder of the year, would provide a translational benefit of approximately £10m for the full year.

Financial Position

The Group has generated strong cash flows in Q3, benefitting from Malaysian land sale and South African business sale receipts of £21m and £13m respectively. Net debt has reduced from £215m at 30 June to £159m at 30 September 2016.

The Group balance sheet remains strong with net debt/EBITDA ratio at circa 1.1x.

Outlook

The Board's expectations for Full Year 2016 remain unchanged from the interim results in August. Looking forward, the outlook in 2017 also remains consistent with our previous expectations underpinned by resilient trading in Europe despite a challenging macroeconomic environment, the Asian Nitrile market continuing to evolve broadly in line with our expectations and the ongoing integration of Hexion PAC.

 

Capital Markets Day

Synthomer plc will be hosting a Capital Markets Day for analysts and investors on Thursday December 1st. Senior members of Synthomer's management team will provide an update on strategy as well as present on the Group's two core divisions and R&D and innovation capabilities.

-ENDS-

ENQUIRIES:

Calum MacLean, Chief Executive Officer

Charles Armitstead

Stephen Bennett, Chief Financial Officer

Teneo Blue Rubicon

Tel: + 44 1279 436211

Tel: + 44 207 260 2700

 

 

The Company will hold a conference call for investors and analysts at 0800 GMT today. 

Please dial +44 (0) 808 2370030 entering conference ID: 31555005# to gain access to the call.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTBPBLTMBTMBBF
Date   Source Headline
9th Oct 20233:08 pmRNSHolding(s) in Company
9th Oct 20239:44 amRNSHolding(s) in Company
6th Oct 20231:56 pmRNSHolding(s) in Company
6th Oct 20238:53 amRNSHolding(s) in Company
5th Oct 20232:40 pmRNSDirector/PDMR Shareholding
5th Oct 202312:27 pmRNSHolding(s) in Company
2nd Oct 20232:22 pmRNSHolding(s) in Company
28th Sep 20237:00 amRNSAdmission of Nil Paid Rights
27th Sep 20237:00 amRNSDespatch of PALs
26th Sep 20237:00 amRNSCapital Reorganisation
25th Sep 20231:58 pmRNSResults of General Meeting
22nd Sep 20233:21 pmRNSAdditional Listing
7th Sep 20233:44 pmRNSPublication of a Prospectus
7th Sep 20237:00 amRNSRights Issue
7th Sep 20237:00 amRNSHalf-year results
18th Jul 20237:00 amRNSPost-close trading update
12th Jul 20233:17 pmRNSAppointment of Non-Executive Director
28th Jun 202312:37 pmRNSDirector/PDMR Shareholding
28th Jun 202312:36 pmRNSDirector/PDMR Shareholding
22nd Jun 202310:20 amRNSDirector/PDMR Shareholding
16th May 20234:00 pmRNSResult of AGM
16th May 20237:00 amRNSAGM trading update
12th May 20231:08 pmRNSDirector/PDMR Shareholding
12th May 20231:06 pmRNSDirector/PDMR Shareholding
13th Apr 202310:02 amRNSHolding(s) in Company
12th Apr 20235:52 pmRNS2022 Annual Financial Report & Notice of 2023 AGM
11th Apr 20237:00 amRNSDirector/PDMR Shareholding
11th Apr 20237:00 amRNSDirector/PDMR Shareholding
29th Mar 20237:00 amRNSDirector/PDMR Shareholding
29th Mar 20237:00 amRNSDirector/PDMR Shareholding
29th Mar 20237:00 amRNSDirector/PDMR Shareholding
28th Mar 20237:00 amRNSFinal Results
21st Mar 20237:00 amRNSRefinancing
28th Feb 20233:33 pmRNSDisposal
31st Jan 20237:00 amRNSPost-close update for the year ended 31 Dec 2022
11th Jan 202311:30 amRNSResult of General Meeting
16th Dec 202212:12 pmRNSPublication of Circular &Notice of General Meeting
13th Dec 20227:00 amRNSProposed Sale of Laminates, Films & Coated Fabrics
8th Dec 20227:00 amRNSDirector/PDMR Shareholding
30th Nov 20227:00 amRNSBoard changes
29th Nov 202211:16 amRNSOutcome of European Commission investigation
1st Nov 20222:53 pmRNSHolding(s) in Company
27th Oct 202210:27 amRNSHolding(s) in Company
25th Oct 20227:00 amRNSDirector/PDMR Shareholding
25th Oct 20227:00 amRNSDirector/PDMR Shareholding
20th Oct 20227:00 amRNSCovenant relaxation to the end of 2023 agreed
13th Oct 20227:00 amRNSHolding(s) in Company
12th Oct 20227:00 amRNSInvestor Seminar
6th Oct 20227:00 amRNSDirector/PDMR Shareholding
6th Oct 20227:00 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.